AI-enhanced low-dose CT to screen for pancreatic cancer
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
This project will test whether an AI tool called PANDA can read low-dose CT scans to find early pancreatic cancer in people aged 50 and older.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400000 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 5 sites (Shanghai, Shanghai Municipality and 4 other locations) |
| Trial ID | NCT07117045 on ClinicalTrials.gov |
What this trial studies
This prospective, multicenter observational cohort uses the PANDA artificial intelligence system to analyze low-dose CT (LDCT) images collected at participating centers. When PANDA flags an abnormality, a multidisciplinary team (MDT) reviews the finding and decides whether to recall the person for further testing, create a personalized follow-up plan, or monitor for at least one year. Primary outcomes include pancreatic cancer detection rate and positive predictive value, with secondary tracking of follow-up pathways and diagnostic yield. The protocol enrolls people aged 50 and older who complete LDCT, excluding those with prior pancreatic cancer, recent acute pancreatitis, or poor-quality scans.
Who should consider this trial
Good fit: Ideal candidates are adults aged 50 or older who undergo LDCT, can give informed consent, and have no prior pancreatic cancer or recent severe abdominal inflammation.
Not a fit: People with a history of pancreatic cancer, recent acute pancreatitis, or LDCT scans of poor quality are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could enable earlier, less invasive detection of pancreatic cancer from routine low-dose CT scans, improving chances for curative treatment.
How similar studies have performed: Previous multi-center and real-world testing of PANDA and similar AI tools has reported high sensitivity and specificity for pancreatic lesion detection across tens of thousands of cases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 50 years and above. 2. Voluntary signing of informed consent. 3. Completion of LDCT examination. Exclusion Criteria: 1. Previous history of pancreatic cancer. 2. Abdominal inflammation or diagnosis of acute pancreatitis within 6 months. 3. Poor image quality due to ascites, pancreatic trauma, thoracic/abdominal surgery, radiotherapy or chemotherapy. 4. Research subjects unable to complete follow-up due to physical or other reasons.
Where this trial is running
Shanghai, Shanghai Municipality and 4 other locations
- Meinian Onehealth Healthcare Holdings Co., Ltd — Shanghai, Shanghai Municipality, China (Recruiting)
- Ruici Medical Examination Institution — Shanghai, Shanghai Municipality, China (Recruiting)
- Changhai Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
- Jiaxing University Affiliated Second Hospital — Jiaxing, Zhejiang, China (Recruiting)
- Ningbo University Affiliated People's Hospital — Ningbo, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Wang Bei Lei, M.D.
- Email: lilly_wang@126.com
- Phone: 13774238083
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.